Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- LLNW +8.7%, ADBE +8%, WBC +3.6%, WGO +2.4%, VZ +2.4%, SON+2.1%, URI +1.9%, (also will resume its pre-existing $1 billion program to repurchase shares of its common stock), IIIN +1.8%, DHR +1.6%, BDN+1.5%, TRV +1.5%, RCI +1.4%, DGX +0.5%, POOL +0.5%
Other news:
- CNAT +4.7% (Conatus Pharma announces that the European Medicines Agency has granted orphan designation to Conatus' drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis (PSC), a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure)
- ADHD +28.3% (merger partner Arcturus enters research collaboration and worldwide license agreement with Janssen)
- CEI +23.5% (low cap / thinly traded name higher after company discloses Interim CEO, Richard Azar, has released a letter to shareholders)
- ONCS +16.4% (presents updated Phase 2 data from patients treated w/ ImmunoPulse as a monotherapy versus the combination of ImmunoPulse IL-12 and pembrolizumab)
- BLFS +9.8% (customer Kite Pharma Receives FDA Approval for Yescarta)
- PSTI +8.6% (FDA grants Pluristem orphan drug designation for cell therapy as treatment for acute radiation syndrome)
- BLCM +4.2% (higher following Kite CAR T news)
- JUNO +3.3% (higher following Kite CAR T news)
- RDHL +2.2% (granted orphan drug designation by the FDA for upamostat for the treatment of pancreatic cancer)
- GILD +2% (Gilead Sciences' Kite confirms Yescarta FDA approval as first CAR T therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy )
- DPW +1.9% (agrees to issue and sell 452,239 shares of common stock in subscription agreements at $0.67 per share)
- BMRN +1.2% (rebounding from yesterday's weakness on development portfolio update/reaffirmed guidance)
Analyst comments:
- EIGR +1.7% (initiated with a Buy at ROTH Capital)